SAGE Therapeutics (SAGE) Received its Third Buy in a Row


After Piper Jaffray and Oppenheimer gave SAGE Therapeutics (NASDAQ: SAGE) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics today and set a price target of $207. The company’s shares opened today at $159.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 28.9% and a 54.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Scholar Rock Holding Corp.

Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $200.64, implying a 26.2% upside from current levels. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $206 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $188.82 and a one-year low of $79.88. Currently, SAGE Therapeutics has an average volume of 649.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.